EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 286-293

  Tortella, Frank C ^a   Rose, Jany ^a   Robles, Lydia ^a   Moreton, J Edward ^b   Hughes, Jhon ^c   Hunter, John C ^c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAM 569; ENADOLINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ELECTROENCEPHALOGRAM; ENANTIOMER; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SLOW WAVE SLEEP; SPECTROSCOPY; STEREOSPECIFICITY;

ANIMALS; BENZOFURANS; ELECTROENCEPHALOGRAPHY; MALE; NARCOTICS; NEUROPROTECTIVE AGENTS; PYRROLES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; THIOPHENES;

EID: 0030881531     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. CAMPI, C. C. AND CLARKE, G. D.: Effects of highly selective k-opioid agonists on EEG power spectra and behavioral correlates in conscious rats. Pharmacol. Biochem. Behav. 51: 611-616, 1995.
2. CARRUYO, L., FLORIO, V., LONG, V. G. AND SCOTTI DE CAROLIS, A.: The effects of narcotics and narcotic antagonists on the electrical activity of the brain. In: Pain, ed. by A. Soulairac, J. Cahn and J. Carpenter, pp. 425-439, Academic Press, New York, 1968.
3. CLARK, C. R., BIRCHMORE, B., SHARIF, N. A., HUNTER, J. C., HILL, R. G. AND HUGHES, J.: PD117302: A selective agonist for the k-opioid receptor. Br. J. Pharmacol. 93: 618-626, 1988.
4. COLASANTI, B. AND KHAZAN, N.: Agonists properties of narcotic analgesics and antagonists on the electroencephalogram and behavior in the rat and their reversal by naloxone. Neuropharmacology 12: 619-626, 1973.
5. DAVIS, R. E., CALLAHAN, M. J., DICKERSON, M. AND DOWNS, D. A.: Pharmacological activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys. J. Pharmacol. Exp. Ther. 261: 1044-1049, 1992.
6. DAWKINS, R., LEBSACK, M. E., WRIGHT, S. AND POSVAR, E. L.: Rising, single dose tolerance, pharmacokinetics and pharmacodynamics of intramuscular CI-977. J. Clin. Pharmacol. 31: 864, 1991.
7. DIMPFEL, W., SPULER, M. AND BORBE, H. O.: Monitoring of the effects of antidepressant drugs in the freely moving rat by radioelectroencephalography (Tele-Stereo-EEG). Neuropsychobiology 19: 116-120, 1988.
8. DIMPFEL, W., SPULER, M. AND NICHOLS, D. E.: Hallucinogenic and stimulatory amphetamine derivatives: Fingerprinting DOM, DOI, DOB, MDMA, and MDBD by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG). Psychopharmacology 98: 297-303, 1989.
9. DIONNE, R. A., DOBBINS, K. R. AND HARGREAVES, K. M.: Evaluation of a kappa opioid agonist, spiradoline, in comparison to morphine and placebo in the oral surgery model. Clin. Pharmacol. Ther. 49: 183, 1991.
10. HAERTZEN, C. A.: Subjective effects of narcotic antagonists cyclazocine and nalorphine in the Addiction Research Center Inventory (ARC). Psychopharmacologia 18: 366-377, 1970.
11. HALFPENNY, P. R., HORWELL, D. C., HUGHES, J., HUNTER, J. C. AND REES, D. C.: Highly selective k-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexy-1]arylacetamide derivatives. J. Med. Chem. 33: 286-291, 1989.
12. HAYES, A. G., BIRCH, P. P. AND CAVICCHINI, E.: Evidence that the kappa agonist U50488H has non-opioid actions. J. Pharm. Pharmacol. 40: 718-720, 1988.
13. HILL, M. P. AND BROTCHIE, J. M.: Modulation of glutamate release by a k-opioid receptor agonist in rodent and primate striatum. Eur. J. Pharmacol. 281: R1-R2, 1995.
14. HJORTH, B.: The physical significance of the time domain descriptors in EEG analysis. Electroencephogr. Clin. Neurophysiol. 34: 321-325, 1973.
15. HUNTER, J. C., LEIGHTON, G. E., MEECHAM, K. G., BOYLE, S. J., HORWELL, D. C., REES, D. C. AND HUGHES, J.: CI-977, a novel and selective agonist for the k-opioid receptor. Br. J. Pharmacol. 101: 183-189, 1990.
16. KHAZAN, N.: Implications and significance of EEG and sleep-awake activity in the study of experimental drug dependence on morphine. In: Methods in Narcotic Research, ed. by S. Ehrenpreis and A. Neidle, pp. 173-215, Marcel Dekker, New York, 1975.
17. KUMOR, K. M., HAERTZEN, C. A., JOHNSON, R. E., KOCHER, T. AND JASINSKI, D.: Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J. Pharmacol. Exp. Ther. 238: 960-968, 1986.
18. LAMBERT, P. D., WOODRUFF, G. N., HUGHES, J. AND HUNTER, J. C.: Inhibition of L-glutamate release: A possible mechanism of action for the neuroprotective effects of the k-selective agonist CI-977. Mol. Neuropharmacol. 1: 77-82, 1991.
19. LEIGHTON, G. E., JOHNSON, M. A., MEECHAM, K. G., HILL, R. G. AND HUGHES, J.: Pharmacological profile of PD117302, a selective k-opioid agonist. Br. J. Pharmacol. 92: 915-922, 1987.
20. MACKAY, K. B., KUSUMOTO, K., GRAHAM, D. I. AND MCCULLOCH, J.: Focal cerebral ischemia in the cat: Pretreatment with a kappa-1 opioid receptor agonist, CI-977. Brain Res. 618: 213-219, 1993.
21. MARQUIS, K. L., PAQUETTE, N. C., GUSSIO, R. P. AND MORETON, J. E.: Comparative electroencephalographic and behavioral effects of phencyclidine, (+)-SKF-10,047 and MK-801 in rats. J. Pharmacol. Exp. Ther. 231: 1104-1112, 1989.
22. MATTIA, A. AND MORETON, J. E.: Electroencephalographic (EEG), EEG power spectra, and behavioral correlates in rats given phencyclidine. Neuropharmacology 25: 763-769, 1986.
23. MCLAUGHLIN, C. R., TAO, Q. AND ABOOD, M. E.: Analysis of the antinociceptive actions of the k-opioid agonist enadoline (CI-977) in neonatal and adult rats: Comparison to k-opioid receptor mRNA ontogeny. Drug Alcohol Depend. 38: 261-269, 1995.
24. MEECHAM, K. G., BOYLE, S. J., HUNTER, J. C. AND HUGHES, J.: An in vitro profile of activity for the (+) and (-) enantiomers of spiradoline and PD117302. Eur. J. Pharmacol. 173: 151-157, 1989.
25. MILLAN, M. J.: k-opioid receptors and analgesia. Trends Pharmacol. Sci. 11: 70-76, 1990.
26. MILLAN, M. H., CHAPMAN, A. G. AND MELDRUM, B. S.: dual inhibitory action of enadoline (CI977) on release of amino acids in the rat hippocampus. Eur. J. Pharmacol. 279: 75-81, 1995.
27. PETERS, G. AND GAYLOR, S.: Human central nervous system (CNS) effects of a selective kappa opioid agonist. Clin. Pharmacol. Ther. 45: 130, 1989.
28. PFEIFFER, A., BRANTI, V., HERZ, A. AND EMRICH, H. M.: Psychotomimesis mediated by k opiate receptors. Science 233: 774-776, 1986.
29. PINNOCK, R. D.: A highly selective k-opioid receptor agonist, CI-977, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro. Neuroscience 47: 87-94, 1992.
30. REECE, P. A., SEDMAN, A. J., ROSE, S., WRIGHT, S., DAWKTNS, R. AND RAJAGOPALAN, R.: Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappaopioid agonist (CI-977) in humans. J. Clin. Pharmacol. 34: 1126-1132, 1994.
31. REES, D. C.: Chemical structures and biological activities of non-peptide selective kappa opioid ligands. Prog. Med. Chem, 29: 109-139, 1992.
32. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York, 1987.
33. TORTELLA, F. C.: Opioids: Epilepsy and neuroprotection. In: Handbook of Experimental Pharmacology, ed. by A. Herz, Vol. 104(II), pp. 343-360, Springer-Verlag, Heidelberg, 1993.
34. TORTELLA, F. C., COWAN, A. AND ADLER, M. W.: EEG and behavioral effects of ethylketocyclazocine, morphine and cyclazocine in rats: Differential sensitivities towards naloxone. Neuropharmacology 19: 845-850, 1980.
35. TORTELLA, F. C. AND DECOSTER, M. A.: Kappa opioids: Therapeutic considerations in epilepsy and CNS injury. Clin. Neuropharmacology 17: 403-416, 1994.
36. TORTELLA, F. C., ECHEVARRIA, E., LIPOWSKI, A. W., TAKEMORI, A. E., PORTOGHESE, P. S. AND HOLADAY, J. W.: Selective kappa antagonist properties of norbinaltorphimine in the rat maximal electroshock seizure model. Life Sci. 44: 661-665, 1989.
37. TORTELLA, F. C. AND HILL, R. G.: EEG seizure activity and behavioral neurotoxicity produced by (+)-MK801 and (+)-HA966, but not the glycine site antagonist L687,414, in the rat. Neuropharmacology 35: 441-148, 1996.
38. TORTELLA, F. C. AND ROBLES, L.: EEG spectral analysis of various high affinity sigma ligands. Neurosci. Abstr. 17: 194, 1991.
39. TORTELLA, F. C., ROBLES, L., HUNTER, J. C. AND HUGHES, J.: EEG profile of the kappa opioid spiradoline: A stereoisomer analysis. Fed. Proc. 4: A596, 1990.
40. TORTELLA, F. C., ROBLES, L. AND MOSBERG, H. I.: Evidence for mu opioid receptor mediation of enkephalin-induced electroencephalographic seizures. J. Pharmacol. Exp. Ther. 240: 571-577, 1987.
41. YOUNG, G. A.: Dissociation of naloxone-sensitive and naloxone-insensitive effects of U-50,488H. Pharmacol. Biochem. Behav. 33: 215-217, 1989.
42. YOUNG, G. A., HUDSON, G. M., STAMIDIS, H. AND STEINFELS, G. F.: Interactions between U-50,488H or σ receptor antagonists: EEG, EEG power spectral and behavioral correlates. Eur. J. Pharmacol. 231: 473-476, 1993.
43. YOUNG, G. A. AND KHAZAN, N.: Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra: Stereospecificity and naloxone antagonism. Neuropharmacology 23: 1161-1165, 1984.
44. YOUNG, G. A., MARQUIS, K. L., PAQUETTE, N. C., GUSSION, R. P. AND KHAZAN, N.: Haloperidol pretreatment unmasks the kappa opioid effects of U-50,488H on cortical EEG and EEG power spectra in rats. Neuropharmacology 28: 881-884, 1989.
45. YOUNG, G. A., NEISTADT, L. AND KHAZAN, N.: Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Res. Commun. Psychol. Psychiatr. Behav. 6: 365-377, 1981.